“Regenerative Technologies in Traumatology and Orthopedics”
On October 29, 2021, the Institute of Cell Therapy took part in a scientific and practical conference with international participation “Regenerative Technologies in Traumatology and Orthopedics”.
The Institute of Cell Therapy presented 2 scientific reports at the conference on the results of a clinical trial “Features of the Use of Allogeneic Mesenchymal Stem Cells of the Placenta (Cell Drug “Chondrostem”) in the Treatment of Knee Osteoarthritis. The results of cell therapy for osteoarthritis of the knee joints are extremely encouraging.
It should be noted that the first patient to undergo a course of cell therapy for osteoarthritis of the knee joints was the director of the Institute of Cell Therapy Cryobank Dr. Galina Lobintseva, Ph.D., holder of the State Prize of Ukraine. A well-known football player Andriy Shevchenko, former head coach of the National Football Team of Ukraine, now head coach of the Italian club Genoa, also received treatment with a cell drug “Chondrostem” (the Institute of Cell Therapy Cryobank).
Speakers from the Institute of Cell Therapy were Dr. Roman Birsa, orthopedist-traumatologist and Dr. Petro Nemtinov, Ph.D., Head of the R&D Department of the ICT Center of Science.
As Dr. Roman Birsa said, patients with stage 2-3 osteoarthritis of the knee joint were divided into 2 groups: the main group was injected intra-articularly the placenta mesenchymal stem cell drug “Chondrostem” (Institute of Cell Therapy Cryobank) and hyaluronic acid, whereas the control group received only injections of hyaluronic acid. Cell therapy was performed on the basis of Kyiv City Clinical Hospital №6 and Institute of Traumatology and Orthopedics of NAMSU.
Before cell therapy, all patients underwent a comprehensive medical examination, which included X-ray examination, MRI, determination of a wide range of biochemical, immunological and cytological parameters. Indications for the introduction of mesenchymal stem cells of the placenta were traumatic and idiopathic osteoarthritis of the knee.
The dosage of the drug “Chondrostem” (the Institute of Cell Therapy Cryobank) was 20 million cells in 2 ml of solution, the cell suspension was stored in liquid nitrogen (-196 C) and defrosted 20-30 minutes before administration. Mesenchymal stem cells of the placenta were injected once a month, three times. After cell therapy, patients were recommended to unload the joint to prevent reactive synovitis. The speaker noted that cell therapy was well tolerated by all patients, no side effects were observed.
Dr. Petro Nemtinov in his report overviewed the statistically processed results of 3 and 6 months follow-up after intra-articular injection of stem cells, noting such positive results of treatment as cartilage thickening, reduction of inflammation and pain relief. Also in patients treated with placental stem cells, a decrease in the formation of osteophytes, increased regeneration processes, immunomodulatory effect of cells were noted. The results of treatment in the group of patients receiving placental mesenchymal stem cells were statistically significantly better than in patients who received injections of hyaluronic acid alone.
Petro Nemtinov explained the positive effect of cell therapy of gonarthrosis by stimulation of the placenta own cartilage stem cells with introduced mesenchymal stem cells and initiation of regeneration processes with the participation of signaling molecules. The speaker also presented the results of experimental studies conducted by Japanese scientists, which showed the advantage of stem cells over collagen gel and self-regeneration in the treatment of osteoarthritis. Both speakers noted that the results of cell therapy are better among younger patients.
More information on the possibilities of storing umbilical cord blood stem cells, umbilical cord, placenta and their use in the treatment of osteoarthritis can be provided at the Institute of Cell Therapy.